Psoriasis Therapeutics in Asia-Pacific Markets, Size, Share & Forecast to 2021

1
Top 10 Diabetes Care Technologies, Devices and
Therapeutics Markets - Growth, Global Share,
Industry Overview, Analysis, Trends Opportunities
and Forecast 2012 - 2020
Psoriasis Therapeutics in Asia-Pacific Markets to
2021 Advent of Novel Biologics and Expanding
Treatment Pool to Drive Growth
2
Summary
Report Overview
GBI Research, the leading business intelligence
provider, has released its latest research,
Psoriasis Therapeutics in Asia-Pacific Markets to
2021 Advent of Novel Biologics and Expanding
Treatment Pool to Drive Growth, which provides
insights into psoriasis therapeutics in the
Asia-Pacific (APAC) market. For the purposes of
this report, APAC refers to the market in China,
India, Japan, and Australia only. The report
estimates the market size for 2014, along with
forecasts until 2021. It also covers disease
epidemiology, treatment algorithms, treatment use
patterns, in-depth analysis of pipeline
molecules, clinical trial failure rates, and
analysis of recent deals. It is built using data
and information sourced from proprietary
databases, primary and secondary research, and
in-house analysis carried out by GBI Researchs
team of industry experts.   Read more details at
http//www.bigmarketresearch.com/psoriasis-therape
utics-in-asia-pacific-to-2021-advent-of-novel-biol
ogics-and-expanding-treatment-pool-to-drive-growth
-market
3
Key Benefits
Key Benefits
In 2014, the value of the psoriasis therapeutics
market in APAC amounted to an estimated 690m,
and it is forecast to grow at a Compound Annual
Growth Rate (CAGR) of 8.4 between 2014 and 2021
to reach 1.2 billion. The psoriasis treatment
landscape is a particularly complex one. More
than 80 of patients fall into the
mild-or-moderate category, for which the first
line of treatment is topical drugs, phototherapy,
or a combination. In the case of severe
patients, non-steroidal drugs such as
methotrexate, cyclosporine, and acitretin are
practiced as first-line treatment however, they
come with toxicity concerns and so cannot be
prescribed for long durations. Biologics such as
TNF inhibitors (adalimumab, etanercept,
infliximab) and ustekinumab are largely
prescribed as second-line therapy when none of
the aforementioned options provide the desired
results. However, during the forecast period,
biologics are likely gain a significant patient
share due to healthcare plans in APAC and
awareness regarding the effectiveness of
biologics. Among the recently launched biologics,
Cosentyx (secukinumab) from Novartis has shown
better efficacy than Enbrel (etanercept), and is
a novel molecule that targets Interluekin-17
(IL-7). Biocon India has launched Alzumab
(itolizumab), which is a first-in-class novel
molecule that targets CD6 protein.
4
Key Benefits
Scope
The report analyzes treatment use patterns,
market characterization, the pipeline, and key
licensing and co-development deals for psoriasis
in the APAC markets of China, India, Japan, and
Australia.The report includes - A brief
introduction to psoriasis, including
pathophysiology, etiology, diagnosis, and
treatment algorithms - In-depth analysis of
currently marketed drugs, including analysis of
safety, efficacy, treatment patterns, and
strengths/weaknesses, along with a heat map
comparing them in terms of safety and efficacy -
A comprehensive review of the pipeline for
psoriasis, including individual analysis of a
number of late-stage pipeline drugs likely to
enter the market during the forecast period the
pipeline is further analyzed on the basis of
phase distribution, molecule type, program type,
mechanism of action, and molecular target -
Additional in-depth analysis of pipeline drug
clinical trials by phase, trial size, trial
duration, and program failure rate for each
molecule type - Multi-scenario forecast data for
the market to 2021, taking into account how it
might be affected by the introduction of new
drugs, the expiry of key patents on current
drugs, and changes in disease epidemiology across
the key developed markets
5
Table of Contents
1 Table of Contents 5 2 Introduction 9 3
Marketed Products 18 4 Psoriasis Market to 2021
Pipeline Products 29 5 Market Forecast to 2021
44 6 Deals and Strategic Consolidations 54 7
Appendix 65
6
List of Tables
Table 1 Psoriasis Market, Global, Types of
Psoriasis, 2015 9 Table 2 Psoriasis Market,
Therapeutics, Global, All Pipeline Products,
Discovery, 2014 65 Table 3 Psoriasis Market,
Therapeutics, Global, All Pipeline Products,
Preclinical Phase, 2014 67 Table 4 Psoriasis
Market, Therapeutics, Global, All Pipeline
Products, Preclinical Phase, 2014 70 Table 5
Psoriasis Market, Therapeutics, Global, All
Pipeline Products, Preclinical Phase, 2014
71 Table 6 Psoriasis Market, Therapeutics,
Global, All Pipeline Products, Preclinical Phase,
2014 74 Table 7 Psoriasis Market, Therapeutics,
Global, All Pipeline Products, Preclinical Phase,
2014 78 Table 8 Psoriasis Market, Therapeutics,
Global, All Pipeline Products, Preclinical Phase,
2014 79 Table 9 Psoriasis Market, Asia-Pacific,
Forecast Data, 20142021 79 Table 10 Psoriasis
Market, China, Forecast Data, 20142021 79
7
List of Figures
Figure 1 Psoriasis Market, Global, Composite
Treatment Algorithm, 2015 14 Figure 2 Psoriasis
Market, Global, Humira (adalimumab), Annual Sales
(bn), 20072014 22 Figure 3 Psoriasis Market,
Global, Enbrel (etanercept), Annual Sales (bn),
20072014 23 Figure 4 Psoriasis Market, Global,
Remicade (infliximab), Annual Sales (bn),
20072014 25 Figure 5 Psoriasis Market, Global,
Stelara (ustekinumab), Annual Sales (bn),
20102014 26 Figure 6 Psoriasis Market, Global,
Comparative Safety and Efficacy of Marketed
Products Heatmap (1/2), 2015 27 Figure 7
Psoriasis Market, Global, Comparative Safety and
Efficacy of Marketed Products Heatmap (2/2), 2015
28 Figure 8 Psoriasis Market, Global, Pipeline
by Stage of Development, Program Type and Route
of Administration, 2015 30
8
Enquire about report http//www.bigmarketresearch
.com/report-enquiry/245545